Throughout this proposal, we have emphasized the need to move research findings into the clinic. The new Shared Resource and Methodology dispussed below will provide important new areas of expertise needed by our investigators on both sides of the clinical interface. In order to link the developing shared resources with our Cancer Center members, we propose to use CCSG pilot project support specifically for projects that utilize the new shared resources. 7.5.2.1 TRANSLATIONAL METHODOLOGY PILOT FUNDING! In order to fully utilize the capabilities of the Translational Methodology, we will create a new mechanism for pilot support designed to move a project through from discovery to drug scale-up. Support for a single project funded at $100,000 per year for one year will help ensure that new cancer therapeutics are using this methodology. 7.5.2.2 CLINICAL PHARMACOLOGY PILOT SUPPORT New therapies may fail for many reasons. We are beginning to understand how pharmacokinetics affect benefit and toxicity of many new drugs. Many clinical studies frequently do not incorporate pharmacokinetic, pharmaCodynamic, or pharmacogenetic evaluation into their trial design because of cost. In this pilot mechanism, we will offer support for these types of studies in investigator-initiated clinical trials. The purpose of this mechanism of pilot support is not meant to fund the entire clinical trial Instead, this pilot funding will serve as a supplement to ongoing clinical trials. A total amount of $50,000 per year is committed to this program from CCSG funds. There will be no uniform date for application for this mechanism given the nature of clinical investigation. Instead, this mechanism will be promoted to the Cancer Center membership, and a review of each proposal will be initiated by the Clinical Research Leadership committee and Drs. Jacobson and Kirstein. If the study is deemed to be of sufficient merit, then it will be funded and funds will be expended on a first-come, first-served basis. Other meritorious trials can be supported by philanthropic funds if they are proposed after the CCSG support is committed. In addition to these specific mechanisms, the existing pilot project support will be maintained (TTURC, Women's Cancer, Brainstorm, Population Science, Sarcoma). The CCSG will support some of these mechanisms and may be supplemented with philanthropic support. 7.5.2.3 ONGOING SUPPORT OF EXISTING AWARD MECHANISMS We propose to continue to bur annual Brainstorm awards to promote interprogrammatic research, as well as specific awards in the areas of population sciences and translational research. Although the majority of these awards will be funded through philanthropic support, we have budgeted $200,000 in CCSG support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA077598-15
Application #
8449972
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
15
Fiscal Year
2013
Total Cost
$223,486
Indirect Cost
$75,482
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Sarver, Aaron L; Murray, Collin D; Temiz, Nuri A et al. (2016) MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle 15:881-5
Diep, Caroline H; Knutson, Todd P; Lange, Carol A (2016) Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res 14:141-62
Yun, Young Sung; Kim, Kwan Hyun; Tschida, Barbara et al. (2016) mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress. Mol Cell 61:625-39
Yan, Y; Hanse, E A; Stedman, K et al. (2016) Transcription factor C/EBP-β induces tumor-suppressor phosphatase PHLPP2 through repression of the miR-17-92 cluster in differentiating AML cells. Cell Death Differ 23:1232-42
Beura, Lalit K; Hamilton, Sara E; Bi, Kevin et al. (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-6
Than, B L N; Linnekamp, J F; Starr, T K et al. (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene 35:4179-87
Struntz, Nicholas B; Harki, Daniel A (2016) Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors. ACS Chem Biol 11:1631-8
Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33
Glasgow, Michelle; Vogel, Rachel Isaksson; Burgart, Jennifer et al. (2016) Long term follow-up of a phase II trial of multimodal therapy given in a ""sandwich"" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol Res Pract 3:6
Felices, Martin; Lenvik, Todd R; Davis, Zachary B et al. (2016) Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. Methods Mol Biol 1441:333-46

Showing the most recent 10 out of 763 publications